- ImmuCell Corporation (NASDAQ:ICCC) reported preliminary sales of $6M in the third quarter.
- During the three-month periods ended September 30, annualized production output was approximately 73% of the company’s estimated full capacity of approximately $30M per year.
- As of September 30, 2024, the backlog of orders aggregated approximately $7.3 million.
ImmuCell announces preliminary results for Q3 2024
BlackSky announces proposed public offering of common stock
